The AIB1 (Amplified in Breast Cancer 1) antibody is a critical tool for studying the AIB1 protein, encoded by the *NCOA3* gene. AIB1. also known as SRC-3 (Steroid Receptor Coactivator-3), belongs to the p160 nuclear receptor coactivator family. It functions as a transcriptional coactivator, interacting with nuclear receptors (e.g., estrogen, progesterone, and androgen receptors) to enhance ligand-dependent gene expression. AIB1 plays a pivotal role in hormone signaling pathways, regulating cell proliferation, differentiation, and apoptosis. Its overexpression is linked to tumorigenesis, particularly in hormone-driven cancers like breast, ovarian, and prostate cancer, where it promotes oncogenic growth, metastasis, and therapy resistance.
The AIB1 antibody is widely used in research to detect and quantify AIB1 protein levels in tissues or cell lines via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). It aids in understanding AIB1's role in cancer progression, its interaction with signaling pathways (e.g., EGFR, HER2), and its potential as a therapeutic target. Studies also explore its involvement in metabolic disorders and developmental processes. Commercially available AIB1 antibodies are typically validated for specificity and sensitivity, with applications in both basic research and clinical diagnostics, particularly in stratifying cancer patients for personalized treatments. Ongoing research focuses on elucidating its molecular mechanisms and therapeutic implications in diverse diseases.